CMXC — Cell MedX Share Price
0.000.00%
Last trade - 00:00- $14.27m
- $14.51m
- $0.00m
- 18
- 22
- 31
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 203,819.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -40928.57% | ||
Financial Summary
| Year End 31st May | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.1 | 0.01 | 0.01 | 0 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cell MedX Corp. is a biotechnology company. It is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, general health, pain relief, wellness and alleviate complications associated with medical conditions including, diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney function. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling.
Directors
- Frank Mcenulty CEO (64)
- Yanika Silina CFO (43)
- Joao Da Costa COO (57)
- Bradley Hargreaves VOP (62)
- George Adams IND (70)
- Last Annual
- May 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- March 19th, 2010
- Public Since
- March 11th, 2013
- No. of Shareholders
- 54
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 297,236,373
- Address
- 123 W. Nye Ln, Suite 446, CARSON CITY, 89706
- Web
- https://cellmedx.com/
- Phone
- +1 3105089398
- Auditors
- DALE MATHESON CARR-HILTON LABONTE LLP
Upcoming Events for CMXC
Q4 2024 Cell MedX Corp Earnings Release
Q1 2025 Cell MedX Corp Earnings Release
Similar to CMXC
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Cell MedX share price?
As of Today at 19:05 UTC, shares in Cell MedX are trading at $0.05. This share price information is delayed by 15 minutes.
How has the Cell MedX share price performed this year?
Shares in Cell MedX last closed at $0.05 and the price had moved by +4799900% over the past 365 days. In terms of relative price strength the Cell MedX share price has outperformed the S&P500 Index by +4234791.48% over the past year.
What are the analyst and broker recommendations for Cell MedX?
There is no consensus recommendation for this security.
What is the Cell MedX dividend yield?
Cell MedX does not currently pay a dividend.
Does Cell MedX pay a dividend?
Cell MedX does not currently pay a dividend.
When does Cell MedX next pay dividends?
Cell MedX does not currently pay a dividend.
How do I buy Cell MedX shares?
To buy shares in Cell MedX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cell MedX?
As of the previous close price of $0.05, shares in Cell MedX had a market capitalisation of $14.27m.
Where are Cell MedX shares listed?
Here are the trading details for Cell MedX:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CMXC
What kind of share is Cell MedX?
Based on an overall assessment of its quality, value and momentum Cell MedX is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cell MedX share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Cell MedX share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cell MedX. Over the past six months, its share price has outperformed the S&P500 Index by +128.62%.
As of the last closing price of $0.05, shares in Cell MedX were trading +25.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cell MedX PE Ratio?
The Cell MedX PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cell MedX?
Cell MedX's management team is headed by:
- Frank Mcenulty - CEO
- Yanika Silina - CFO
- Joao Da Costa - COO
- Bradley Hargreaves - VOP
- George Adams - IND